cervical cancer
Conditions
Interventions
control group:Paclitaxel combined with Carboplatin
Sponsors
The First Affiliated Hospital of Xi'an Jiaotong University
Eligibility
Sex/Gender
Female
Inclusion criteria
Inclusion criteria: (1) All patients did not receive any other treatment before their first visit to our hospital; (2) All patients were pathologically diagnosed as cervical cancer; (3) Gynecological examination was conducted by 2 or more gynecological experts and with the diagnosis of 2018 FIGO stage IB3,IIA2 (> 4cm), or IIb; (4) Pathological types of cervical squamous cell carcinoma, adenocarcinoma, adenosquamous cell carcinoma; (5) All patients with complete and reliable clinical data; (6) General examination is normal, without chemotherapy and operation contraindications; (7) All patients signed the condition and treatment protocol consent; (8) All patients undergo extensive abdominal hysterectomy + para-aortic lymphadenectomy via + pelvic lymph node dissection. Young patients with squamous cell carcinoma could retain one or both ovaries with a signed informed consent.
Exclusion criteria
Exclusion criteria: (1) Patients with tumor other than cervical cancer or previous history of chemotherapy; (2) Metastatic cervical cancer or special type of cervical cancer; (3) In lactation or pregnancy of cervical cancer patients; (4) Other diseases that cannot tolerate surgery or chemotherapy; (5) Patients with stage IB3 and i1a2 who were directly treated with concurrent chemoradiotherapy after imaging or gynecological examination evaluation or patients with tumor diameter >6cm.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Changes in tumor tissue size;the surgical resection rate;the operating time;the intraoperative blood loss;whether it is a R0 operation; | — |
Countries
China
Contacts
Public ContactLi Qiling
The First Affiliated Hospital of Xi'an Jiaotong University
Outcome results
None listed